Innoviva Strategy and Business Model

Executive Overview

Innoviva is a healthcare company with two distinct but complementary economic engines: a high-margin royalty portfolio tied to GlaxoSmithKline (GSK) respiratory medicines and a growing specialty therapeutics business focused on serious infections and acute-care hospital products. The company traces its roots to Theravance, founded in 1996, and adopted the Innoviva name in 2018. Innoviva is headquartered in Burlingame, California.

Strategically, Innoviva has been repositioning from a royalty collection vehicle into a more diversified specialty pharmaceutical platform. Its legacy royalty interests in products such as Trelegy Ellipta, Anoro Ellipta, and Breo/Relvar Ellipta still provide the company’s core cash-generation engine. More recently, acquisitions including La Jolla Pharmaceutical and Entasis Therapeutics added owned commercial products such as GIAPREZA, XERAVA, and Xacduro, giving Innoviva a direct operating presence in hospital anti-infectives and critical care.

The business is operationally centered in the United States but has global economic exposure through partner-sold respiratory products. As of FY2024, Innoviva reported revenue of #N/A, reflecting this mix of recurring royalty income and product sales.

Innoviva at a Glance

Logo
Common name	Innoviva
Full legal name	Innoviva, Inc.
Headquarters	Burlingame, California, United States
Ownership	Public company; no controlling shareholder publicly disclosed
Ticker	INVA
Exchange	NASDAQ
Market Cap	$1.74B
Revenue (FY2024)	#N/A
Founding / major historical milestones	Founded in 1996 as Theravance; 2014 separation of Theravance Biopharma; renamed Innoviva in 2018; acquired La Jolla Pharmaceutical in 2022; acquired Entasis Therapeutics in 2023
Industry or industries	Pharmaceuticals, biotechnology, specialty therapeutics, healthcare royalties
Key products or services	Respiratory royalty interests; GIAPREZA; XERAVA; Xacduro; healthcare portfolio investments
Geographic footprint	U.S.-centered operations with global royalty exposure through GSK-marketed respiratory products
Business segments as officially reported	Innoviva has emphasized consolidated reporting; as of FY2024, its main economic revenue streams were royalty revenue and net product sales
Company website	https://www.innoviva.com/

1. What Is the Strategy of Innoviva?

Innoviva’s public positioning since its portfolio expansion in 2022 and 2023 suggests a clear strategic shift: preserve and maximize the cash flow from legacy respiratory royalties while using that cash flow to build a more diversified specialty therapeutics business, with particular emphasis on anti-infectives and hospital-based medicines. Using the Playing to Win framework, the strategy can be summarized as follows.

1. 1a. What is the winning aspiration of Innoviva?

   Innoviva’s practical winning aspiration is to evolve from a company largely defined by one royalty stream into a broader healthcare platform with durable cash generation, owned commercial products, and selective pipeline upside. In public materials through FY2024, management has emphasized diversification, capital discipline, and building a meaningful presence in serious infectious disease and acute care. Innoviva has not centered its public messaging on a single long-term revenue target; instead, its aspiration appears to be portfolio transformation without giving up the financial advantages of its royalty base.

2. 1b. Where does Innoviva play?

   Innoviva plays in two main arenas. First, it participates globally in respiratory medicine economics through royalty rights tied to GSK-marketed products, especially the Ellipta franchise. Second, it plays directly in U.S.-centered specialty pharmaceuticals, particularly hospital anti-infectives and critical-care therapies. It has also extended its scope through strategic investments and subsidiaries focused on infectious disease, including bacteriophage therapy through Armata Pharmaceuticals.

3. 1c. How does Innoviva plan to win?

   Innoviva is not trying to win through scale in primary-care pharma. Its model is narrower. It plans to win by combining a cash-rich royalty engine with targeted acquisitions, licenses, and commercialization of medicines in areas with high unmet need, limited direct competition, and specialist buyers. In effect, Innoviva is using royalty cash flow to buy and build niche pharmaceutical assets that can be promoted through a relatively focused commercial infrastructure rather than a very large sales organization.

4. 1d. What capabilities must Innoviva have in place?

   To make that strategy work, Innoviva needs strong capital allocation, business development, deal integration, regulatory execution, medical affairs, hospital market access, and specialty sales capabilities. It also needs forecasting and counterparty-management capability for its royalty stream, plus pharmaceutical quality and supply oversight for its owned products. Because the company is part holding company and part operating pharma company, portfolio management is itself a core capability.

5. 1e. What management systems does Innoviva require?

   Innoviva needs management systems that support both a royalty business and a product company: disciplined capital allocation reviews, launch and formulary-adoption tracking, pipeline milestone governance, pharmaceutical compliance and quality controls, and scenario planning around patent life, competitive entries, and royalty trajectories. It also needs integration processes for acquired companies and products, because M&A has been central to its strategic repositioning.

2. What Are the Current Strategic Initiatives of Innoviva?

Based on recent annual reporting, investor communications, and deal activity through FY2024, Innoviva’s most important strategic initiatives appear to be the following.

• Maximizing the value of the respiratory royalty portfolio.

  Innoviva continues to depend on royalties from GSK’s respiratory products for a large share of its cash generation. In practical terms, that means monitoring the performance of Trelegy Ellipta, Anoro Ellipta, Breo/Relvar Ellipta, and related products, while managing exposure to patent life, prescribing trends, and competitive respiratory therapies.

• Building Innoviva Specialty Therapeutics into a more substantive hospital franchise.

  The company’s acquisitions of La Jolla Pharmaceutical and Entasis Therapeutics were not standalone financial trades; they were part of a broader platform-building effort. Innoviva has been integrating these assets into a more coherent acute-care business that can market multiple products into hospitals and health systems.

• Driving uptake of Xacduro after its 2023 U.S. approval.

  Xacduro is strategically important because it gives Innoviva a differentiated anti-infective asset for a difficult hospital setting: resistant Acinetobacter infections associated with hospital-acquired and ventilator-associated bacterial pneumonia. Commercially, the initiative is less about mass prescribing and more about targeted formulary wins, infectious-disease specialist education, and antibiotic-stewardship acceptance.

• Expanding the contribution of GIAPREZA and XERAVA.

  These products came from the La Jolla acquisition and broadened Innoviva’s exposure to acute care. The strategic task is to improve execution in hospital accounts, refine account targeting, and make the commercial platform more efficient across multiple products rather than selling each product in isolation.

• Maintaining an anti-infectives pipeline and adjacent innovation optionality.

  Innoviva’s R&D posture appears focused rather than broad. Through Entasis and Armata, it has maintained exposure to drug-resistant pathogens and novel treatment approaches. This matters strategically because anti-infectives require scientific credibility and lifecycle investment even when the commercial footprint is relatively small.

• Using capital allocation and business development as strategic tools.

  Innoviva’s public actions show that portfolio construction is central to its strategy. The company has used royalty cash flows and balance-sheet capacity to acquire commercial products, pipeline assets, and strategic stakes. That makes screening, valuation, integration, and post-deal operating discipline ongoing strategic initiatives rather than occasional events.

3. What Is the Business Model of Innoviva?

Innoviva’s business model is unusual because it combines a royalty company and a specialty pharmaceutical operating company inside one public entity.

What customers actually buy. In the royalty part of the model, Innoviva is not selling products directly to patients or doctors; it earns a contractual share of sales generated by GSK’s respiratory products. In the operating pharma part of the model, hospitals and healthcare providers ultimately buy or prescribe Innoviva’s branded therapies such as GIAPREZA, XERAVA, and Xacduro.

Recurring versus one-time revenue. Royalty revenue is the most recurring part of the model because it is tied to ongoing sales of established respiratory medicines. Product revenue is also repeat-driven rather than one-time, but it is more variable because hospital adoption depends on formulary access, specialist usage, distributor inventory, and clinical practice patterns.

How pricing power works. Innoviva’s pricing power is indirect in royalties because GSK controls commercialization and pricing of the respiratory products. In owned hospital products, Innoviva has more direct pricing authority, but pricing is constrained by hospital budgets, antimicrobial stewardship, reimbursement realities, and the existence of lower-cost generic substitutes in adjacent categories.

Why the business mix matters. The mix matters because royalties are typically much higher margin and lower working capital than direct product sales. That means even modest changes in royalty performance can have outsized impact on cash generation. By contrast, owned products require selling expense, medical affairs, supply management, and gross-to-net adjustments, but they also give Innoviva more strategic control and potential pipeline upside.

What drives gross margin, operating margin, and cash generation. Royalty revenue usually carries very high gross margin because there is little associated cost of goods sold. Product gross margin depends on manufacturing economics, distributor terms, and commercial scale. Operating margin is influenced by sales-force costs, R&D spending, and acquired intangible amortization. Cash generation is still anchored by the royalty stream, while the specialty therapeutics business is more operationally intensive.

Revenue model. Innoviva is not a subscription or pay-per-use company. Its model is a blend of sales-based royalty revenue and repeat pharmaceutical product sales, supplemented by strategic investments and pipeline optionality.

4. What Products and/or Services Does Innoviva Sell?

Innoviva’s portfolio is best understood in two groups: legacy royalty-bearing respiratory products and directly commercialized specialty therapeutics.

• Royalty-bearing respiratory products.

  The most important economic assets in this category are GSK-marketed inhaled respiratory medicines, including Trelegy Ellipta, Anoro Ellipta, Breo/Relvar Ellipta, and Arnuity Ellipta. These products are strategically important because they underpin Innoviva’s cash flow, even though Innoviva does not market them itself.

• GIAPREZA.

  GIAPREZA is angiotensin II, a hospital product used in distributive or septic shock settings. It is a specialty acute-care medicine sold into highly specific clinical workflows.

• XERAVA.

  XERAVA is eravacycline, an antibiotic approved for complicated intra-abdominal infections. It fits Innoviva’s broader anti-infectives strategy, though it serves a narrower market than mass-market antibiotics.

• Xacduro.

  Xacduro, acquired through Entasis, is a major newer strategic product. It addresses serious infections caused by susceptible Acinetobacter baumannii-calcoaceticus complex in hospital settings, making it both clinically important and commercially targeted.

• Pipeline and strategic investment exposure.

  Beyond marketed products, Innoviva has exposure to infectious-disease development programs through acquired subsidiaries and investments, including bacteriophage therapy programs at Armata. These do not drive current revenue in the same way as royalties or marketed products, but they matter strategically.

The royalty-bearing respiratory portfolio has historically been the most important driver of cash flow, while Xacduro and the hospital portfolio are more important to the company’s strategic repositioning.

5. What Are the Key Competitors or Peers of Innoviva?

Innoviva does not have one simple competitor set because its economics come from both royalties and direct specialty product sales. The relevant competitors therefore differ by revenue stream.

GSK is not a competitor; it is Innoviva’s partner and the marketer of the respiratory products from which Innoviva earns royalties.

6. What Is the Marketing Strategy of Innoviva?

Innoviva’s marketing strategy is highly segmented because the company does not market all of the products that generate its revenue.

For the respiratory royalty portfolio, Innoviva effectively relies on GSK’s marketing, sales, payer access, and brand-building capabilities. Innoviva benefits economically from those activities but does not control them directly.

For its owned specialty therapeutics, Innoviva’s marketing approach is much more focused and clinical. It is built around hospital account targeting, medical education, formulary access, infectious-disease specialist engagement, and support for antimicrobial stewardship discussions. That is very different from broad direct-to-consumer or large-scale primary-care promotion.

In this model, marketing is a supporting capability rather than the sole source of advantage. Clinical differentiation, formulary acceptance, and specialized field execution matter more than mass-market brand spend. For products such as Xacduro and XERAVA, the company needs credible scientific communication and precise targeting more than broad awareness campaigns.

7. What Are the Key Customer Segments of Innoviva?

Innoviva’s customer base is concentrated and mixed.

• GSK as economic counterparty.

  For the royalty business, Innoviva’s economics depend heavily on GSK’s ability to sell respiratory products. That makes GSK the most important commercial counterparty in Innoviva’s model, even though end patients and prescribers are the ultimate users.

• Hospitals and health systems.

  For GIAPREZA, XERAVA, and Xacduro, the key customers are acute-care hospitals, integrated delivery networks, and hospital purchasing organizations. These accounts matter because formulary decisions can determine repeat demand.

• Clinical decision-makers.

  Infectious-disease physicians, intensivists, pharmacists, and pharmacy-and-therapeutics committees are central to product adoption. In hospital pharma, these clinical gatekeepers are often as important as the formal purchasing customer.

• Wholesalers and specialty distributors.

  These intermediaries are Innoviva’s immediate product customers for many sales transactions, even though the true demand comes from hospitals and clinicians.

• Potential partners and collaborators.

  For pipeline assets and ex-U.S. opportunities, partners can also be customers in an economic sense through licensing, commercialization, or development arrangements.

Overall, Innoviva is not broadly diversified across thousands of equally important end markets. It remains economically concentrated in respiratory royalties and a relatively narrow acute-care customer base.

8. What Is the Sales Model of Innoviva?

Innoviva’s sales model has two parts.

Royalty model. The company does not directly sell the respiratory products that generate its royalty revenue. Instead, it receives contractually defined royalties based on partner sales, chiefly from GSK. In that sense, part of Innoviva’s sales model is passive from a field-force perspective but highly leveraged financially.

Specialty product model. For its owned hospital medicines, Innoviva uses a focused specialty sales approach. Products are typically sold through wholesalers or specialty distributors and then pulled through by a targeted field organization working with hospital accounts, infectious-disease specialists, critical-care physicians, and formulary committees.

This channel structure affects growth in several ways. Formulary wins can create repeat ordering and make revenue more durable. At the same time, hospital buying cycles are slow, stewardship considerations can cap volume, and distributor stocking can create short-term revenue variability. The model supports deeper customer intimacy in a narrow set of accounts, but it does not have the scale economics of mass-market pharma.

For consultants, this matters because many of Innoviva’s commercial challenges are executional: account segmentation, pull-through after formulary approval, pricing and contracting, and sales-force productivity in a highly specialized market.

9. In What Geographies Does Innoviva Operate?

Innoviva is operationally concentrated in the United States, where its headquarters and core specialty therapeutics activities are based. Its commercial products are primarily oriented toward the U.S. hospital market.

Economically, however, Innoviva has a broader footprint because its respiratory royalties are tied to products sold by GSK in multiple countries. That means Innoviva has indirect exposure to the United States, Europe, and other markets where the Ellipta franchise is sold.

Its subsidiary and investment footprint also extends beyond a single office location. Acquired businesses and controlled investments have added capabilities and personnel in different U.S. life-science hubs. Even so, Innoviva does not appear to have the kind of large global manufacturing and sales infrastructure typical of major pharmaceutical companies. It is better described as a U.S.-centered specialty pharma and healthcare holding company with global royalty exposure.

10. Who Are the Owners of Innoviva?

Innoviva is a publicly traded company listed under the ticker INVA. As of the latest proxy and public institutional ownership disclosures available around FY2024, ownership was primarily institutional, with large asset managers such as BlackRock and The Vanguard Group among notable shareholders. No single shareholder was publicly disclosed as holding a majority controlling stake.

As with many small- to mid-cap healthcare companies, the shareholder base can include both long-only institutions and more active healthcare-focused investors, so ownership should be viewed as dispersed rather than founder-controlled or family-controlled.

11. How Is Innoviva Organized?

At a practical level, Innoviva is organized as a parent healthcare company overseeing a mix of royalty interests, operating pharmaceutical assets, and strategic investments.

The parent company allocates capital, manages the royalty platform, and oversees portfolio strategy. Beneath that, Innoviva Specialty Therapeutics functions as the main commercial operating platform for owned hospital products. Acquired assets from La Jolla Pharmaceutical and Entasis Therapeutics have expanded that platform. Innoviva has also held a majority ownership position in Armata Pharmaceuticals, which adds a separate innovation and investment dimension to the structure.

Public reporting has generally emphasized consolidated financial results rather than a highly granular segment structure. That means the best way to understand the company is not through many formal reporting segments, but through its underlying operating logic: a cash-generative royalty engine, a specialty therapeutics business, and a set of portfolio investments and pipeline assets.

12. How Does Innoviva Operate?

Innoviva’s day-to-day operations are more complex than those of a pure royalty trust but lighter than those of a fully integrated large pharmaceutical company.

• Royalty administration.

  The company monitors partner sales, accrues royalty income, evaluates market trends in respiratory medicine, and manages contractual and forecasting issues related to the GSK collaboration.

• Commercial operations.

  For owned products, Innoviva manages product supply, gross-to-net deductions, distributor relationships, market access, field sales, and medical affairs. In hospital pharma, execution often depends on relatively small numbers of accounts and specialist prescribers.

• Regulatory and clinical activities.

  The company must support approved products through pharmacovigilance, quality systems, lifecycle evidence generation, and post-approval commercial support. It also manages development programs and investment oversight in infectious disease.

• Portfolio and capital allocation management.

  Because Innoviva has used acquisitions and strategic investments to reshape itself, management must continuously decide how much cash to direct toward launches, development, M&A, balance-sheet management, and potential shareholder returns.

The main operational complexities are concentration risk in the royalty stream, slow hospital adoption cycles, the need for reliable pharmaceutical supply, and the challenge of integrating acquired assets into a coherent commercial platform.

13. What Are the Growth Opportunities for Innoviva?

Innoviva’s most plausible growth opportunities come from a mix of royalty optimization, commercial execution, and further portfolio development.

• Continued royalty strength from Trelegy and the broader Ellipta portfolio.

  As long as the GSK respiratory franchise remains resilient, Innoviva benefits from a high-margin revenue source that can fund other growth initiatives.

• Xacduro adoption in resistant hospital infections.

  Xacduro addresses a serious unmet need in a narrow but clinically important market. If Innoviva can improve awareness, formulary penetration, and real-world usage in the right hospital settings, it could become a meaningful growth driver.

• Better commercialization of GIAPREZA and XERAVA.

  These products offer upside if Innoviva can improve account coverage, field execution, and economic positioning within hospital systems.

• Additional business development.

  Innoviva has already shown that acquisitions and licenses are part of its playbook. Further deals in anti-infectives, acute care, or adjacent specialty pharma are a logical avenue for growth.

• Pipeline optionality through infectious-disease innovation.

  Programs inherited through Entasis and exposure to Armata’s bacteriophage platform provide longer-dated upside if clinical progress translates into approvable or partnerable products.

• International partnering.

  For some owned or acquired products, ex-U.S. deals could provide non-dilutive growth without requiring Innoviva to build a large overseas commercial infrastructure.

Main constraints. The company also faces meaningful limits: dependence on a royalty stream with eventual patent-life risk, narrow hospital markets, antibiotic stewardship that can slow volumes, supply-chain and manufacturing dependencies, and the execution challenge of integrating multiple acquired assets into a small-to-mid-sized operating model.

14. What Is the History of Innoviva?

Innoviva traces its roots to Theravance, which was founded in 1996 in the San Francisco Bay Area. Theravance built a significant collaboration with GSK focused on respiratory medicines, and that collaboration became the foundation for the royalty assets that still shape Innoviva’s economics.

In 2014, Theravance separated its biopharmaceutical operations into Theravance Biopharma, leaving the legacy royalty-focused entity in place. In 2018, Theravance, Inc. changed its name to Innoviva, reflecting a broader ambition beyond its original identity.

The next major phase in Innoviva’s history was portfolio transformation through M&A. In 2022, the company acquired La Jolla Pharmaceutical, adding GIAPREZA and XERAVA. In 2023, it acquired Entasis Therapeutics, adding Xacduro and further deepening its anti-infectives focus. Around this period, Innoviva also built a controlling position in Armata Pharmaceuticals, increasing its exposure to novel infectious-disease therapies.

The broad historical arc is clear: Innoviva started as a science-based respiratory collaboration company, became known primarily for royalty cash flows, and has since been trying to evolve into a more diversified specialty therapeutics and healthcare portfolio company.

15. What Are the Key Assets of Innoviva?

Innoviva’s most important assets are not factories or a massive sales force. They are primarily rights-based and portfolio-based assets.

• Respiratory royalty interests.

  These are the company’s core financial assets. The royalty streams tied to GSK’s respiratory products have historically generated substantial cash and remain strategically central.

• Approved commercial products.

  GIAPREZA, XERAVA, and Xacduro are critical operating assets because they give Innoviva direct exposure to specialty pharma economics and a platform for hospital commercialization.

• Regulatory approvals, intellectual property, and product rights.

  In pharma, these intangible assets often matter more than physical assets. Innoviva’s ability to commercialize and defend its products depends heavily on exclusivity, labeling, and contractual rights.

• Innoviva Specialty Therapeutics commercial infrastructure.

  Though smaller than that of large pharma companies, this infrastructure is strategically important because it allows Innoviva to sell directly into hospital settings.

• Equity stakes and controlled investments.

  The company’s majority-owned position in Armata and other healthcare investments add optionality and strategic breadth.

• Cash flow and liquidity generated by royalties.

  For Innoviva, financial flexibility itself is an asset. Royalty cash flows support acquisitions, development spending, and portfolio management.

So while Innoviva operates in pharma, it is not especially asset-heavy in the manufacturing sense. Its key assets are economic rights, approved products, and capital allocation flexibility.

16. What Is the R&D Strategy of Innoviva?

Innoviva’s R&D strategy appears focused and selective rather than broad-based. It is not trying to replicate the discovery engine of a large research pharmaceutical company. Instead, it has concentrated on infectious disease, resistant pathogens, and assets that can fit a specialty commercial model.

The acquisition of Entasis was central to this approach because it added anti-infective science and led to Xacduro, an FDA-approved product in 2023. Post-approval, the company’s R&D work is likely to include lifecycle evidence generation, medical support, and targeted development activities that strengthen the commercial value of acquired assets.

Innoviva’s exposure to Armata adds another dimension. Armata has been developing bacteriophage therapies, including programs targeting pathogens such as Pseudomonas aeruginosa and Staphylococcus aureus. These are scientifically differentiated programs, though they are also higher risk and longer dated than Innoviva’s marketed products.

Overall, Innoviva’s R&D strategy is best understood as targeted capability building around serious infectious disease, supported by acquisitions, subsidiary platforms, and selective internal development rather than by a very broad internal discovery budget.

17. What Is the Finance Strategy of Innoviva?

Innoviva’s finance strategy is closely tied to the unusual structure of its business. The company has historically benefited from a cash-generative royalty stream that requires relatively little working capital. That gives management flexibility to redeploy capital into acquisitions, product launches, R&D, strategic investments, debt management, and shareholder-return actions when appropriate.

The key financial challenge is balancing a high-margin legacy business against a lower-margin but more controllable operating business. Royalty revenues can produce strong cash conversion, while owned pharmaceutical products require commercial investment, inventory management, and development spending. As a result, capital allocation discipline is central to Innoviva’s financial model.

Public actions suggest that Innoviva’s finance strategy has prioritized three things: preserving liquidity, using capital to diversify away from pure royalty dependence, and maintaining flexibility for additional portfolio moves. In practice, that means finance is not just a back-office function at Innoviva; it is part of the company’s core corporate strategy.

For investors and operators alike, the main finance questions are how long the royalty engine can remain a strong cash source, how efficiently the company can scale its owned products, and whether acquisitions create returns above the cost of capital.

18. What Major Acquisitions Has Innoviva Made?

Acquisitions have played an important role in Innoviva’s transformation from a royalty-focused company into a broader specialty therapeutics platform.

• La Jolla Pharmaceutical Company (acquired in 2022).

  This deal added GIAPREZA and XERAVA, giving Innoviva a direct commercial presence in hospital and acute-care medicines. It was a foundational move in building Innoviva Specialty Therapeutics.

• Entasis Therapeutics Holdings Inc. (acquired in 2023).

  This acquisition added Xacduro and strengthened Innoviva’s focus on anti-infectives and drug-resistant pathogens. Strategically, it was a capability and portfolio deal, not just a single-product transaction.

• Armata Pharmaceuticals stake-building.

  Innoviva has built a controlling ownership position in Armata through staged investments and share purchases rather than a single clean acquisition event. This has given Innoviva exposure to bacteriophage therapy and a novel infectious-disease modality while Armata has remained strategically distinct.

The pattern is notable: Innoviva has used M&A less for scale consolidation and more for portfolio reshaping, capability expansion, and entry into narrower, clinically differentiated markets where its focused operating model can make sense.

19. How Companies Like Innoviva Leverage Independent Consultants through Umbrex

Innoviva’s strategy creates a need for highly specialized, flexible consulting support: portfolio strategy, hospital-commercial execution, infectious-disease market analysis, M&A integration, and data-driven capital allocation. Umbrex has built a global community of more than 8,000 independent management consultants based in over 50 countries. These consultants are alumni of McKinsey, Bain, BCG, and other top firms. Companies like Innoviva use Umbrex when they need that level of problem-solving capability without hiring a full consulting team with all the overhead. Umbrex consultants work across strategy, operations, organization, marketing, sales, finance, technology, ERP, and AI.

• Assess Innoviva’s portfolio strategy, including how to balance respiratory royalty cash flows against investment in specialty therapeutics and pipeline assets.
• Build a launch-acceleration plan for Xacduro, including account prioritization, formulary conversion tactics, and infectious-disease specialist targeting.
• Redesign the hospital sales model for GIAPREZA, XERAVA, and Xacduro to improve productivity across a shared specialty sales force.
• Optimize pricing, contracting, and gross-to-net management for acute-care products sold through wholesalers and hospital channels.
• Create a business-development screen for anti-infective and critical-care acquisition or licensing targets that fit Innoviva’s focused operating model.
• Run post-merger integration workstreams for acquired products or subsidiaries, including operating-model design, synergy tracking, and governance.
• Evaluate manufacturing and supply risk across third-party production, inventory planning, and hospital distribution for specialty products.
• Develop a capital-allocation framework that compares acquisitions, pipeline investment, debt reduction, and share repurchases on a risk-adjusted basis.
• Build market-access and formulary analytics tools that help Innoviva understand where additional medical-affairs support can unlock adoption.
• Apply AI and advanced analytics to sales forecasting, account targeting, medical-insight capture, and commercial scenario planning.